拟6亿投建研发生产基地 润本股份于2023年10月上市，主要从事个人护理类、驱蚊类产品的研发、生产和销售，目前已形成婴童护理产 品、驱蚊产品、精油产品三大核心产品系列。 5月6日晚间，润本股份发布的公告显示，公司拟在广州市黄埔区中新广州知识城国际生物医药创新园投建新的产 研基地(投资标的名称：润本生物技术研发生产基地项目)，持续巩固公司的C2M供应链壁垒，满足未来持续增长 的产销研需求。 公告显示，上述项目投资金额为6亿元，建设内容主要包含办公区、研发区、生活区、生产制造区、园区配套工 程，用于开展个护用品、化妆品、医疗器械、医药制造行业相关产品的研发、生产制造及其配套服务。 实际上，在中新广州知识城国际生物医药创新园，润本股份已重金投入生产项目。 2024年，润本股份率先竞得位于中新广州知识城国际生物医药创新园，凤亨一路以北，凤亨二路以南，康联三路 以西ZSCB-E3-3地块，面积约3.2953万平方米的国有建设用地使用权，并于当年9月审议通过《关于签署投入产出 监管协议暨对外投资的议案》，同意公司以自有或自筹资金投资7亿元建设"润本智能智造未来工厂项目"。 在业绩持续提升之时，润本股份（603193）(6 ...

[Table_Title] 证券研究报告 / 公司点评报告 产品渠道齐发力，业绩持续高增 报告摘要： [Table_Summary] 事件： 润本股份发布 2024 年报及 2025 年一季报，2024 年公司实现营收 13.18 亿元/+27.61%，归母净利润 3.00 亿元/+32.80%，扣非归母净利润 2.89 亿元/+32.28%，非经常性损益 0.11 亿元，主要来自政府补助和公允价 值变动损益。2024Q4 公司实现营收 2.81 亿元/+34.01%，归母净利润 0.39 亿元/-13.28%，扣非归母净利润 0.33 亿元/-19.57%。拟每 10 股派 发现金红利 2.30 元（含税）。2025Q1 实现营收 2.40 亿元/+44.00%，归 母净利润 0.44 亿元/+24.60%，扣非归母净利润 0.39 亿元/+ 22.85%。 点评： 多产品多渠道全面推进，收入维持快增。2024 年公司实现营收 13.18 亿元/+27.61%，分产品看：1）驱蚊产品营收 4.39 亿元/占比 33.33%/ +35.39%，其中销量+25.89%。2）婴童护理产品营收 6.90 亿元/占比 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of —— yuan over the next 6 months [1]. Core Insights - The company continues to experience high revenue growth, with a diversified product matrix [2]. - The revenue for 2024 is projected to be 13.2 billion yuan, representing a year-on-year growth of 27.6%, while the net profit attributable to the parent company is expected to reach 3.0 billion yuan, up 32.8% year-on-year [9]. - The company has a strong focus on the baby care and mosquito repellent segments, which are expected to show good growth potential [9][10]. Financial Performance Summary - Revenue and Profit Forecast: - 2024A: Revenue of 13.18 billion yuan, net profit of 3.00 billion yuan - 2025E: Revenue of 17.72 billion yuan, net profit of 3.92 billion yuan - 2026E: Revenue of 22.99 billion yuan, net profit of 5.05 billion yuan - 2027E: Revenue of 28.79 billion yuan, net profit of 6.36 billion yuan - Growth Rates: - Revenue growth rates are projected at 27.61% for 2024, 34.39% for 2025, 29.77% for 2026, and 25.22% for 2027 - Net profit growth rates are expected to be 32.80% for 2024, 30.52% for 2025, 28.78% for 2026, and 26.05% for 2027 [4][11]. Product and Market Analysis - The company has successfully increased the average selling price of its baby care products, with significant room for further price increases compared to competitors [9]. - The product matrix has been continuously enriched, with over 90 new or upgraded products launched in 2024, including children's sunscreen and egg yolk oil series [9]. - Online sales channels have shown rapid growth, with significant contributions from platforms like Douyin, while offline channels are also expanding [9]. Profitability Metrics - The overall gross margin for 2024 is projected at 58.2%, with a net profit margin of 22.8% [9]. - The company is expected to maintain a healthy return on equity (ROE), projected to be 14.43% in 2024, increasing to 19.19% by 2027 [4][11].

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Views - The company reported a revenue of 1.32 billion yuan in 2024, representing a year-on-year increase of 27.6%, and a net profit attributable to shareholders of 300 million yuan, up 32.8% year-on-year [5] - The company is expected to maintain strong growth in the baby care segment and continue to launch new products to capture market share [8] Company Overview - Latest closing price: 35.58 yuan - Total shares: 4.05 billion, circulating shares: 1.03 billion - Total market capitalization: 14.4 billion yuan, circulating market capitalization: 3.7 billion yuan - 52-week high/low: 36.53/16.13 yuan - Debt-to-asset ratio: 6.3% - Price-to-earnings ratio: 48.08 [4] Financial Performance - In Q4 2024, the company achieved revenue and net profit of 280 million yuan and 40 million yuan, respectively, with year-on-year growth of 34% and a decline of 13% [5] - In Q1 2025, revenue and net profit were 240 million yuan and 44 million yuan, respectively, with year-on-year growth of 44% and 25% [5] - The gross profit margin for 2024 increased by 1.8 percentage points to 58.2% [7] - The company expects net profits of 390 million yuan, 500 million yuan, and 604 million yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 36 times, 29 times, and 24 times [8][11] Revenue Breakdown - In 2024, revenue from mosquito repellent, baby care, and essential oils was 440 million yuan, 690 million yuan, and 160 million yuan, respectively, with year-on-year growth of 35%, 32%, and 8% [6] - For Q1 2025, the revenue growth rates for mosquito repellent, baby care, and essential oils were 66%, 11%, and -6%, respectively [6] - Online direct sales and non-platform distributors showed strong performance, with revenue growth of 24.8% and 39.6% in 2024 [6]

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Views - The company reported a revenue of 1.32 billion yuan in 2024, representing a year-on-year increase of 27.6%, and a net profit attributable to shareholders of 300 million yuan, up 32.8% year-on-year [5] - The company is expected to maintain strong growth in the baby care segment and continue launching new products to capture market share [8] Company Overview - Latest closing price: 35.58 yuan - Total shares: 4.05 billion, circulating shares: 1.03 billion - Total market capitalization: 14.4 billion yuan, circulating market capitalization: 3.7 billion yuan - 52-week high/low: 36.53/16.13 yuan - Debt-to-asset ratio: 6.3% - Price-to-earnings ratio: 48.08 [4] Financial Performance - In Q4 2024, the company achieved revenue and net profit of 280 million yuan and 40 million yuan, respectively, with year-on-year growth of 34% and a decline of 13% [5] - In Q1 2025, revenue and net profit were 240 million yuan and 44 million yuan, respectively, with year-on-year growth of 44% and 25% [5] - The gross profit margin for 2024 increased by 1.8 percentage points to 58.2% [7] - The company expects net profits of 390 million yuan, 500 million yuan, and 604 million yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 36 times, 29 times, and 24 times [8][11] Revenue Breakdown - In 2024, revenue from mosquito repellent, baby care, and essential oils was 440 million yuan, 690 million yuan, and 160 million yuan, respectively, with year-on-year growth of 35%, 32%, and 8% [6] - For Q1 2025, revenue growth rates for mosquito repellent, baby care, and essential oils were 66%, 11%, and -6%, respectively [6] - Online direct sales and non-platform distributors showed strong performance, with revenue growth of 24.8% and 39.6% in 2024 [6]

股票简称：润本股份 股票代码：603193 润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 二〇二三年十月十六日 特别提示 润本生物技术股份有限公司（以下简称"润本股份"、"发行人"、"本 公司"或"公司"）股票将于 2023 年 10 月 17 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素， 在新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明与提示 本上市公告书部分表格中单项数据加总数与表格合计数可能存在微小差 异，均因计算过程中的四舍五入所形成。 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市 初期的投资风险，广大投资者应充分了解交易风险、理性参与新股交易。 具体而言，上市初期的风险包括但不限于以下几种： （一）涨跌幅限制放宽带来的股票交易风险 本公司及全体 ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （上会稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 润本生物技术股份有限公司 招股 ...

保荐人（主承销商） 润本生物技术股份有限公司 （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （申报稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 Runben Biotechnology Co., Ltd. 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 1-1-2 润本生物技术股份有 ...